Granulocyte Colony-Stimulating Factor
-
Subject Areas on Research
-
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.
-
5-Oxo-eicosanoids and hematopoietic cytokines cooperate in stimulating neutrophil function and the mitogen-activated protein kinase pathway.
-
70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808.
-
A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT-2), a Phase III, Randomized, Double-Blind Trial.
-
A G-CSF-secreting adrenal carcinoma with rhabdoid-like differentiation causing leukocytosis.
-
A Novel Analytic Technique to Measure Associations Between Circulating Biomarkers and Physical Performance Across the Adult Life Span.
-
A case of atypical Bartonella henselae infection in a patient with methimazole-induced agranulocytosis.
-
A comparative study of the generation of dendritic cells from mobilized peripheral blood progenitor cells of patients undergoing high-dose chemotherapy.
-
A novel approach to maintain planned dose chemotherapy on time: a decision-making tool to improve patient care.
-
A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer.
-
A phase I trial of recombinant human interleukin-1 beta (OCT-43) following high-dose chemotherapy and autologous bone marrow transplantation.
-
A phase I/II study of high-dose cyclophosphamide, cisplatin, and thioTEPA followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignancies.
-
A phase II study evaluating the efficacy of carboplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in patients with stage IIIB and IV non-small cell lung cancer and extensive small cell lung cancer.
-
A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813.
-
A phase II study of paclitaxel and granulocyte colony-stimulating factor in previously untreated patients with extensive-stage small cell lung cancer: a study of the North Central Cancer Treatment Group.
-
A phase II trial of carboplatin/vinorelbine with pegfilgrastim support for the treatment of patients with advanced non-small cell lung cancer.
-
A phase II trial of high dose carboplatin and paclitaxel with G-CSF and peripheral blood stem cell support followed by surgery and/or chest radiation in patients with stage III non-small cell lung cancer: CALGB 9531.
-
A pilot study of dose-intensified procarbazine, CCNU, vincristine for poor prognosis brain tumors utilizing fibronectin-assisted, retroviral-mediated modification of CD34+ peripheral blood cells with O6-methylguanine DNA methyltransferase.
-
A radiologic syndrome after high dose chemotherapy and autologous bone marrow transplantation, with clinical and pathologic features of systemic candidiasis.
-
A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia.
-
A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111.
-
A randomized phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and filgrastim in high-risk breast cancer patients.
-
A randomized phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study.
-
A randomized study of erythropoietin and granulocyte colony-stimulating factor (G-CSF) versus placebo and G-CSF for patients with Hodgkin's and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation.
-
A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting.
-
A study of filgrastim (rG-CSF) priming of etoposide/cisplatin in advanced non-small cell lung cancer.
-
A systematic literature review of the efficacy, effectiveness, and safety of filgrastim.
-
ALPS-Like Phenotype Caused by ADA2 Deficiency Rescued by Allogeneic Hematopoietic Stem Cell Transplantation.
-
Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review.
-
Agents under investigation for the treatment and prevention of neutropenia.
-
Alterations in L-selectin expression and elastase activity in neutrophils from patients receiving granulocyte colony-stimulating factor alone or in conjunction with high-dose chemotherapy with autologous bone marrow transplantation.
-
Assessing patients' risk of febrile neutropenia: is there a correlation between physician-assessed risk and model-predicted risk?
-
Carcinoma of an unknown primary site: a chemotherapy strategy based on histological differentiation--results of a prospective study.
-
Case Report: Consistent disease manifestations with a staggered time course in two identical twins affected by adenosine deaminase 2 deficiency.
-
Cellular FLIP Inhibits Myeloid Cell Activation by Suppressing Selective Innate Signaling.
-
Changes in actin state and chemotactic peptide receptor expression in granulocytes during cytokine administration after autologous bone marrow transplantation.
-
Clinical benefits of pegylated proteins in oncology.
-
Clinical uses of pegylated pharmaceuticals in oncology.
-
Clostridium septicum abscess in hepatic metastases: successful medical management.
-
Colony stimulating factors for chemotherapy induced febrile neutropenia.
-
Colony-stimulating factor use in the context of refined risk and benefit assessments.
-
Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy.
-
Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.
-
Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials.
-
Cost-benefit analysis of granulocyte colony-stimulating factor in the management of elderly cancer patients.
-
Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States.
-
Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States.
-
Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy.
-
Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer.
-
Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma.
-
Cytokine use and survival in the first-line treatment of ovarian cancer: a Gynecologic Oncology Group Study.
-
Cytokine-induced mobilization of circulating endothelial progenitor cells enhances repair of injured arteries.
-
Development of Aggressive Pancreatic Ductal Adenocarcinomas Depends on Granulocyte Colony Stimulating Factor Secretion in Carcinoma Cells.
-
Development of a novel preclinical model of pneumococcal pneumonia in nonhuman primates.
-
Developments in Neurovascular Diseases and Treatments.
-
Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy.
-
Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854.
-
Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel.
-
EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.
-
Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy.
-
Economic evaluation of filgrastim, sargramostim, and sequential sargramostim and filgrastim after myelosuppressive chemotherapy.
-
Economic impact of granulopoiesis stimulating agents on the management of febrile neutropenia.
-
Effect of primary prophylactic G-CSF use on systemic therapy administration for elderly breast cancer patients.
-
Effect of primary prophylactic granulocyte-colony stimulating factor use on incidence of neutropenia hospitalizations for elderly early-stage breast cancer patients receiving chemotherapy.
-
Effectiveness of Granulocyte Colony-Stimulating Factor in Hospitalized Infants with Neutropenia.
-
Effectiveness of etoposide chemomobilization in lymphoma patients undergoing auto-SCT.
-
Effects of hematopoietic growth factors following myeloablation in a primate model.
-
Efficacy and safety of hematopoietic stem cell remobilization with plerixafor+G-CSF in adult patients with germ cell tumors.
-
Enrichment of peripheral blood stem cells in a primate model following administration of a single dose of rh-IL-1 beta.
-
Epidermal Growth Factor and Granulocyte Colony Stimulating Factor Signaling Are Synergistic for Hematopoietic Regeneration.
-
Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases.
-
Evaluation of Hematopoietic Stem Cell Mobilization Rates with Early Plerixafor Administration for Adult Stem Cell Transplantation.
-
Evaluation of pre-radiotherapy cyclophosphamide in patients with newly diagnosed glioblastoma multiforme. Writing Committee for The Brain Tumor Center at Duke.
-
Ex vivo generation of dendritic cells from cryopreserved, post-induction chemotherapy, mobilized leukapheresis from pediatric patients with medulloblastoma.
-
Extramedullary hematopoiesis during therapy with granulocyte colony-stimulating factor.
-
Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis.
-
Filgrastim in patients with neutropenia: potential effects on quality of life.
-
First global consensus for evidence-based management of the hematopoietic syndrome resulting from exposure to ionizing radiation.
-
Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma.
-
Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies.
-
Fourteen-day CHOP supported with granulocyte colony-stimulating factor in patients with aggressive non-Hodgkin's lymphoma: results of a phase II study.
-
Free-riding and the prisoner's dilemma: problems in funding economic analyses of phase III cancer clinical trials.
-
Frequent detection of tumor cells in hematopoietic grafts in neuroblastoma and Ewing's sarcoma.
-
G-CSF and peripheral blood progenitor cells.
-
G-CSF as prophylaxis of febrile neutropenia in SCLC.
-
G-CSF for fever and neutropenia induced by chemotherapy.
-
G-CSF induces a potentially tolerant gene and immunophenotype profile in T cells in vivo.
-
GW112, a novel antiapoptotic protein that promotes tumor growth.
-
Genomic loss of miR-486 regulates tumor progression and the OLFM4 antiapoptotic factor in gastric cancer.
-
Granulocyte colony-stimulating factor "mobilized" peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy.
-
Granulocyte colony-stimulating factor after allogeneic bone marrow transplantation.
-
Granulocyte colony-stimulating factor mobilized peripheral blood stem cells enter into G1 of the cell cycle and express higher levels of amphotropic retrovirus receptor mRNA.
-
Granulocyte colony-stimulating factors and risk of acute myeloid leukemia and myelodysplastic syndrome.
-
Granulocyte colony-stimulating factors: finding the right indication.
-
Granulocyte-colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and Leukemia Group B study 9022.
-
Granulocyte-colony stimulating factor use and medical costs after initial adjuvant chemotherapy in older patients with early-stage breast cancer.
-
Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence.
-
Hematopoietic growth factors in cancer chemotherapy.
-
Hematopoietic growth factors in the reduction of chemotherapeutic toxicity.
-
Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications.
-
Hematopoietic recovery following high-dose combined alkylating-agent chemotherapy and autologous bone marrow support in patients in phase-I clinical trials of colony-stimulating factors: G-CSF, GM-CSF, IL-1, IL-2, M-CSF.
-
High dose CHOP: a phase II study of initial treatment in aggressive non-Hodgkin lymphoma. Cancer and Leukemia Group B 9351.
-
High dose cyclophosphamide plus recombinant human granulocyte-colony stimulating factor (rhG-CSF) in the treatment of follicular, low grade non-Hodgkin's lymphoma: CALGB 9150.
-
High dose cyclophosphamide with carboplatin: a tolerable regimen suitable for dose intensification in children with solid tumors.
-
High levels of granulocyte and granulocyte-macrophage colony-stimulating factors in cord blood of normal full-term neonates.
-
High-dose chemotherapy and hematopoietic support for patients with high-risk primary breast cancer and involvement of 4 to 9 lymph nodes.
-
High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. City of Hope Bone Marrow Oncology Team.
-
High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study.
-
High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes.
-
High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.
-
High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234.
-
High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer.
-
How do I provide leukapheresis products? Blood center experience and evidence for process improvement.
-
Human thymic epithelial cells produce granulocyte and macrophage colony-stimulating factors.
-
IL-17A Contributes to the Pathogenesis of Endometriosis by Triggering Proinflammatory Cytokines and Angiogenic Growth Factors.
-
Identification of cancer chemotherapy regimens and patient cohorts in administrative claims: challenges, opportunities, and a proposed algorithm.
-
Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909.
-
Impact of an electronic tool in prescribing primary prophylaxis with ciprofloxacin or granulocyte colony-stimulating factor for breast cancer patients receiving TC chemotherapy.
-
Implementing an evidence-based risk assessment tool to predict chemotherapy-induced neutropenia in women with breast cancer.
-
Improving the management of chemotherapy-induced neutropenia.
-
Incidence and clinical significance of cardiac biomarker elevation during stem cell mobilization, apheresis, and intramyocardial delivery: an analysis from ACT34-CMI.
-
Incidence of acute cellular rejection following granulocyte colony-stimulating factor administration in lung transplantation: A retrospective case-cohort analysis.
-
Inflammation triggers emergency granulopoiesis through a density-dependent feedback mechanism.
-
Influence of filgrastim (granulocyte colony-stimulating factor) on human immunodeficiency virus type 1 RNA in patients with cytomegalovirus retinitis.
-
Intensive outpatient adjuvant therapy for breast cancer: results of dose escalation and quality of life.
-
Interactive discussion on chemotherapy-related adverse events.
-
Introduction: pegfilgrastim, a new era in the management of chemotherapy-induced neutropenia.
-
Large-scale mobilization and isolation of CD34+ cells from normal donors.
-
Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells.
-
Long-term outcomes of myeloid growth factor treatment.
-
Macrophage colony-stimulating factor can modulate immune responses and attract dendritic cells in vivo.
-
Management of chemotherapy in a pregnancy complicated by a large neuroblastoma.
-
Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia.
-
Maternal serum cytokines in preterm premature rupture of membranes.
-
Mobilization and collection of peripheral blood CD34+ cells from patients with Fanconi anemia.
-
Mobilization of dendritic cells from patients with breast cancer into peripheral blood stem cell leukapheresis samples using Flt-3-Ligand and G-CSF or GM-CSF.
-
Mobilization of dendritic cells in cancer patients treated with granulocyte colony-stimulating factor and chemotherapy.
-
Moving forward with myeloid growth factors.
-
Multiple cycles of high dose chemotherapy supported by hematopoietic progenitor cells as treatment for patients with advanced malignancies.
-
Multipotent stem cells in cardiac regenerative therapy.
-
Myeloid growth factors clinical practice guidelines in oncology.
-
Myeloid growth factors.
-
Neutropenia in glycogen storage disease Ib: outcomes for patients treated with granulocyte colony-stimulating factor.
-
Neutrophil growth factors.
-
Non-Cell-Autonomous Activity of the Hemidesmosomal Protein BP180/Collagen XVII in Granulopoiesis in Humanized NC16A Mice.
-
Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia.
-
Outcomes and costs of autologous stem cell mobilization with chemotherapy plus G-CSF vs G-CSF alone.
-
Outcomes of fludarabine, high dose cytarabine and granulocyte-colony stimulating factor (FLAG) as re-induction for residual acute myeloid leukemia on day 14 bone marrow.
-
Overcoming drug resistance in mantle cell lymphoma using a combination of dose-dense and intense therapy.
-
Patients aged > or = 70 are at high risk for neutropenic infection and should receive hemopoietic growth factors when treated with moderately toxic chemotherapy.
-
Pegfilgrastim administered once per cycle reduces incidence of chemotherapy-induced neutropenia.
-
Pegfilgrastim primary prophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy.
-
Pegfilgrastim: a granulocyte colony-stimulating factor with sustained duration of action.
-
Pegfilgrastim: the promise of pegylation fulfilled.
-
Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas.
-
Persistent, therapeutically relevant levels of human granulocyte colony-stimulating factor in mice after systemic delivery of adeno-associated virus vectors.
-
Pharmacoeconomics of the myeloid growth factors: a critical and systematic review.
-
Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor.
-
Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor.
-
Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303).
-
Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study.
-
Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report.
-
Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma.
-
Potential role of granulocyte-monocyte colony-stimulating factor in the progression of intracranial aneurysms.
-
Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy.
-
Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer.
-
Preemptive dosing of plerixafor given to poor stem cell mobilizers on day 5 of G-CSF administration.
-
Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin's lymphoma: cost-effectiveness analyses.
-
Prophylactic colony-stimulating factors in children receiving myelosuppressive chemotherapy: a meta-analysis of randomized controlled trials.
-
Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis.
-
Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?
-
Proposed biosimilar pegfilgrastim (LA-EP2006) compared with reference pegfilgrastim in Asian patients with breast cancer: an exploratory comparison from two Phase III trials.
-
Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732.
-
Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy.
-
Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer.
-
Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma.
-
Recombinant human granulocyte colony-stimulating factor therapy for patients with neutropenia and/or neutrophil dysfunction secondary to glycogen storage disease type 1b.
-
Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.
-
Reduction of oral mucositis by filgrastim (r-metHuG-CSF) in patients receiving chemotherapy.
-
Regulation of leukocyte migration by activation of the leukocyte adhesion molecule-1 (LAM-1) selectin.
-
Regulation of steady-state neutrophil homeostasis by macrophages.
-
Requirement for myeloid growth factors in the differentiation of acute promyelocytic leukaemia.
-
Reversal of radiation-induced neutropenia by granulocyte colony-stimulating factor.
-
Risk and healthcare costs of chemotherapy-induced neutropenic complications in women with metastatic breast cancer.
-
Risk assessment and guidelines for first-cycle colony-stimulating factor use in the management of chemotherapy-induced neutropenia.
-
Safety and efficacy of pegfilgrastim in patients receiving myelosuppressive chemotherapy.
-
Safety of concomitant use of granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor with cytotoxic chemotherapy agents.
-
Short-term costs associated with primary prophylactic G-CSF use during chemotherapy.
-
Single cell RNA-seq reveals profound transcriptional similarity between Barrett's oesophagus and oesophageal submucosal glands.
-
Sources of human and murine hematopoietic stem cells.
-
Stem cell transplantation for the treatment of Fanconi anaemia using a fludarabine-based cytoreductive regimen and T-cell-depleted related HLA-mismatched peripheral blood stem cell grafts.
-
Systemic production of human granulocyte colony-stimulating factor in nonhuman primates by transplantation of genetically modified myoblasts.
-
The economics of febrile neutropenia: implications for the use of colony-stimulating factors.
-
The effect of filgrastim or pegfilgrastim on survival outcomes of patients with cancer receiving myelosuppressive chemotherapy.
-
The efficacy of granulocyte colony-stimulating factor following autologous bone marrow transplantation for non-Hodgkin's lymphoma with monoclonal antibody purged bone marrow.
-
The impact of Filgrastim schedule variation on hematopoietic recovery post-chemotherapy.
-
The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials.
-
The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy.
-
The role of hematopoietic growth factors in support of ifosfamide/carboplatin/etoposide chemotherapy.
-
The use of G-CSF during craniospinal irradiation.
-
Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective.
-
Thrombocytopenia in allogeneic peripheral blood stem cell collections.
-
Transplantation of enriched and purged peripheral blood progenitor cells from a single apheresis product in patients with non-Hodgkin's lymphoma.
-
Update on neutropenia and myeloid growth factors.
-
Vinorelbine (Navelbine)/carboplatin combination therapy: dose intensification with granulocyte colony-stimulating factor.
-
Will biosimilars gain momentum?
-
Keywords of People